Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The prediction for Rigel Pharmaceutical Inc. disappointed with a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Rigel Pharmaceutical Inc. | - | - | - | - |
iShares Core DAX® | -3.429% | 5.085% | 15.455% | 12.600% |
iShares Nasdaq 100 | -6.121% | 0.593% | 16.379% | 27.048% |
iShares Nikkei 225® | -7.364% | 5.479% | 6.970% | -3.061% |
iShares S&P 500 | -4.366% | 2.019% | 18.650% | 32.317% |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)